# Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes

> **NCT07272109** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 210 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Nab-paclitaxel
- **DRUG:** Gemcitabine (1000 mg/m2)
- **OTHER:** Anti-Diabetics
- **OTHER:** Active treatment and monitoring

## Key facts

- **NCT ID:** NCT07272109
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07272109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07272109, "Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07272109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*